Bristol-Myers Squibb Company
Triazolones and tetrazolones as inhibitors of ROCK
Last updated:
Abstract:
The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same. ##STR00001##
Status:
Grant
Type:
Utility
Filling date:
26 May 2017
Issue date:
18 Feb 2020